Saxenda Weight Loss: How It Works and Results

Saxenda weight loss treatment uses liraglutide 3 mg, a once-daily injectable GLP-1 receptor agonist, to help adults manage their weight alongside a reduced-calorie diet and increased physical activity. Licensed in the UK for adults with a BMI of 30 kg/m² or above, Saxenda works by reducing appetite and increasing feelings of fullness. This article explains how Saxenda works, who qualifies for it on the NHS or privately, what weight loss results clinical trials show, which side effects to monitor, and how long treatment typically needs to continue for lasting results.

How does Saxenda actually help you lose weight?

Saxenda reduces appetite and increases fullness by activating GLP-1 receptors in the brain, and must be used alongside a reduced-calorie diet and increased physical activity.

Saxenda (liraglutide 3 mg) helps you lose weight by reducing appetite, slowing gastric emptying, and increasing feelings of fullness after eating. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the action of the naturally occurring hormone GLP-1, which is released from the gut after meals. By activating GLP-1 receptors in the brain, particularly in the hypothalamus, Saxenda signals that the body is satisfied, making it easier to eat less without feeling deprived.

Saxenda is administered as a once-daily subcutaneous injection using a pre-filled pen device. The dose is started low (0.6 mg daily) and increased gradually over five weeks to the full therapeutic dose of 3 mg daily. This step-up approach is designed to reduce the likelihood of gastrointestinal side effects during the early weeks of treatment.

It is important to understand that Saxenda is not a standalone solution. The UK marketing authorisation for Saxenda specifies that it must be used alongside a reduced-calorie diet and increased physical activity.^[1][5] The medicine supports behavioural change rather than replacing it. This page covers adult use; if you are enquiring about use in adolescents, please discuss this with your prescriber or refer to the current UK Summary of Product Characteristics (SmPC) for the full licensed population. Saxenda's mechanism is distinct from that of newer dual or triple receptor agonists, though all GLP-1-based treatments share the core principle of appetite regulation.

Who can get Saxenda for weight loss on the NHS or privately?

NHS access follows NICE guidance and local ICB commissioning decisions, while private prescribing covers adults with a BMI of 30 kg/m² or above, or 27 to 29.9 kg/m² with a weight-related comorbidity.

Saxenda is available in the UK both through NHS specialist services and through private providers, though eligibility criteria differ between the two routes.

On the NHS, access to Saxenda is determined by local Integrated Care Boards (ICBs), which commission weight management services according to NICE guidance. NICE guidance on weight management medicines sets out that liraglutide 3 mg may be recommended for adults with a BMI of 35 kg/m² or above alongside at least one weight-related comorbidity, or for those with a BMI of 30 to 34.9 kg/m² in certain high-risk groups. NHS availability is not automatic following a NICE recommendation, as individual ICBs decide whether and how to commission these services locally.

Privately, the UK marketing authorisation for Saxenda covers adults with a BMI of 30 kg/m² or above, or adults with a BMI of 27 to 29.9 kg/m² who also have at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea. In people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean family background, lower BMI thresholds are recognised in UK clinical practice as indicating equivalent cardiometabolic risk, but these adjusted thresholds inform clinical risk assessment and do not alter the marketing authorisation requirements described above. A prescriber will assess for contraindications and suitability before initiating treatment. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Saxenda is one option a prescriber may consider if it is clinically appropriate.

Saxenda is not suitable for everyone. It should not be used during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment, and if you are planning a pregnancy you should discuss stopping Saxenda with your prescriber in advance, in line with the UK SmPC. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), a history of pancreatitis, or severe gastrointestinal disease should discuss these with their prescriber before starting. Note that in the UK, medullary thyroid carcinoma and MEN2 are listed as precautions rather than contraindications in the UK SmPC; the only contraindication listed is hypersensitivity to liraglutide or any excipient.^[1][17]

How much weight can you realistically expect to lose with Saxenda?

In the SCALE trial, adults using Saxenda lost an average of approximately 8% of body weight over 56 weeks, compared with around 2.6% in the placebo group.

Clinical trial data show that adults using Saxenda alongside lifestyle changes can expect to lose meaningfully more weight than with lifestyle changes alone, though individual results vary considerably. In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., New England Journal of Medicine, 2015), participants using liraglutide 3 mg lost an average of approximately 8% of their body weight over 56 weeks, compared with around 2.6% in the placebo group. Roughly 63% of participants on liraglutide achieved at least 5% weight loss, and around 33% achieved at least 10% weight loss.

These figures represent averages from a clinical trial population and should be interpreted with care. Factors including baseline weight, adherence to dietary and physical activity recommendations, and individual metabolic response all influence outcomes. Some people respond very well and lose substantially more than the trial average, while others may find the medicine less effective.

The UK SmPC for Saxenda and NICE guidance both recommend that treatment should be reviewed after 16 weeks at the full maintenance dose of 3 mg daily. If a person has not lost at least 5% of their initial body weight by that point, Saxenda should be discontinued, as continued use is unlikely to be beneficial. This review point is an important efficacy checkpoint, and patients should be aware of it from the outset so that expectations are realistic and treatment decisions are made collaboratively with a clinician.

What side effects should you watch out for while using Saxenda?

The most common side effects are gastrointestinal, including nausea and vomiting; serious risks include pancreatitis, gallbladder problems, dehydration, and increased resting heart rate.

The most commonly reported side effects of Saxenda are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are most pronounced during the dose escalation phase and typically improve as the body adjusts to the medicine. Eating small, bland meals, eating slowly, avoiding rich or fatty foods, and staying well hydrated can help manage nausea during this period.

More serious but less common adverse effects include:

• Pancreatitis: Acute pancreatitis has been reported in people using liraglutide, including post-marketing reports of necrotising pancreatitis and cases with fatal outcomes.^[9][1] If you develop persistent, severe abdominal pain, particularly if it radiates to the back, stop taking Saxenda and seek urgent medical assessment. Contact your GP promptly or call NHS 111 if you are unsure; call 999 if you develop sudden, severe abdominal pain with collapse or signs of shock.

• Dehydration and kidney injury: Severe vomiting or diarrhoea can lead to dehydration, which may in turn affect kidney function. If you are unable to keep fluids down or have prolonged diarrhoea, seek medical advice promptly.

• Gallbladder problems: Cholelithiasis (gallstones) and cholecystitis have been reported. Symptoms include upper right abdominal pain, fever, and jaundice.

• Heart rate increase: Saxenda can increase resting heart rate.^[1][11] People with pre-existing cardiac conditions should be monitored.

• Hypoglycaemia: This is more likely if Saxenda is used alongside insulin or sulfonylureas.^[1]

Any suspected side effects should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

If you notice a neck lump, persistent hoarseness, or difficulty swallowing, discuss this with your GP.

How long do you need to use Saxenda to keep the weight off?

Saxenda is intended for long-term use, as evidence shows substantial weight regain occurs after stopping; continued treatment is appropriate while the person is tolerating and benefiting from it.

Saxenda is intended for long-term use as part of ongoing chronic weight management, and evidence suggests that weight regain is common after stopping the medicine. The SCALE Maintenance trial (Wadden et al., Lancet, 2015) demonstrated that participants who discontinued liraglutide 3 mg regained a substantial proportion of the weight they had lost during the active treatment phase, highlighting that the medicine's effects are sustained only while it is being used alongside continued lifestyle changes.

There is no fixed maximum duration of treatment specified in the UK licence. Continued use is appropriate provided the person is tolerating the medicine, continues to benefit from it, and the prescriber judges that ongoing treatment remains clinically appropriate. Regular review is recommended to assess ongoing benefit, side effects, and whether treatment goals are being met.

For some people, Saxenda may be a bridge to more sustained behavioural change, while for others it may form part of a longer-term management plan. It is worth noting that other MHRA-authorised medicines for chronic weight management are available in the UK, including semaglutide (Wegovy) and tirzepatide (Mounjaro), which may offer different efficacy or tolerability profiles. A prescriber can help determine which option is most appropriate based on individual circumstances, medical history, and response to treatment. Stopping Saxenda abruptly without a plan for ongoing weight management is likely to result in weight regain, so any decision to discontinue should be made in discussion with a clinician.

Frequently Asked Questions